ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2215

Effect of Single 6 Ml Intraarticular Injection of Hylan G-F 20 in Patients with Knee Osteoarthritis: Results of a Single Centre Study

SUNIL KUMAR PANDEY1 and SAT PAL SINGH2, 1ORTHOPEDIC DEPARTMENT, SAFDARJUNG HOSPITAL, VMMC, NEW DELHI, NEW DELHI, India, 2DEPARTMENT OF MEDICINE, SAFDARJUNG HOSPITAL,VMMC, NEW DELHI, NEW DELHI, India

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Osteoarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: ARHP Osteoarthritis – Clinical Aspects Poster

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: To evaluate the effect of single 6ml intraarticular injection of hylan G-F 20 in patients with knee osteoarthritis.

Author: Dr. Pandey Sunil Kumar*, Dr. Singh Sat Pal*

*Safdarjung hospital, New Delhi

Objective: To evaluate efficacy and effect on analgesic requirement of 6 ml single injection of hylan G-F 20 in patients with primary knee osteoarthritis

Methods: In this prospective study, adult patients with primary knee osteoarthritis (grade II to IV) were treated with 6 ml single intra-articular injection of hylan G-F 20. Patients were followed at 6 and 12 months. Difference in WOMAC score from baseline to 6 and 12 months was evaluated by paired “t” test. Numbers and percentages of patients requiring analgesics on daily basis were recorded at all visits.

Results: A total of 352 patients [male 113 (32.10%); female 239 ((67.90%)] [grade II 197(55.97%), grade III 119 (33.81%) and grade IV 36 (10.23%)] with mean age of 59.10 (4.39) years and mean body mass index 27.20 (3.81) kg/m2 were included in the study. Mean weight and height of the study participants was 68.11 (7.40) kg and 159 (10) cm respectively. One hundred patients (28.41%) patients had varus deformity. Twenty five (7.10%) and 14 (3.98%) patients had effusion in the right and left knee respectively. The WOMAC score from reduced from 64.44(16.89) at baseline to 34.00(10.31) at 6 month and 36 (11.65) at 12 months respectively. The difference in the WOMAC score from baseline to 6 months and 12 months was statistically significant (P<0.001 for both). Number of patients requiring analgesics daily reduced from 28(7.95%)at baseline to 2(0.57%) at 6 months and 3(0.85%) at 12 months.

Conclusion: Single 6 ml injection of hylan G-F was effective and well tolerated in patients with knee osteoarthritis. Hylan G-F 20 also reduced the requirement of analgesics.

Key words: Efficacy, hylan G-F 20, knee osteoarthritis


Disclosure: S. K. PANDEY, None; S. P. SINGH, None.

To cite this abstract in AMA style:

PANDEY SK, SINGH SP. Effect of Single 6 Ml Intraarticular Injection of Hylan G-F 20 in Patients with Knee Osteoarthritis: Results of a Single Centre Study [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effect-of-single-6-ml-intraarticular-injection-of-hylan-g-f-20-in-patients-with-knee-osteoarthritis-results-of-a-single-centre-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-single-6-ml-intraarticular-injection-of-hylan-g-f-20-in-patients-with-knee-osteoarthritis-results-of-a-single-centre-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology